Tocilizumab in addition to standard of care in the management of COVID-19: a meta-analysis of RCTs.

Acta Biomed · 2022 · PMC8972884 · PMID 35315395

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Outcomes Overall Mortality The overall mortality rate was lower in the tocilizumab group compared to the SOC-only group, but the difference did not reach statistical significance (OR, 0.87; 95% CI, 0.73-1.04; I 2 , 15%) ( Fig. 2 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.